ArticleFrontiers in immunology2025

Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study.

Miao Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.